226 related articles for article (PubMed ID: 37122703)
1. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Saleh HA; Mitwasi N; Ullrich M; Kubeil M; Toussaint M; Deuther-Conrad W; Neuber C; Arndt C; R Loureiro L; Kegler A; González Soto KE; Belter B; Rössig C; Pietzsch J; Frenz M; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1166169. PubMed ID: 37122703
[TBL] [Abstract][Full Text] [Related]
2. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.
Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A
Cancer Gene Ther; 2024 Apr; ():. PubMed ID: 38582787
[TBL] [Abstract][Full Text] [Related]
3. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
Soto KEG; Loureiro LR; Bartsch T; Arndt C; Kegler A; Mitwasi N; Drewitz L; Hoffmann L; Saleh HA; Crespo E; Mehnert M; Daglar C; Abken H; Momburg F; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1302354. PubMed ID: 38169746
[TBL] [Abstract][Full Text] [Related]
4. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Kittel-Boselli E; Soto KEG; Loureiro LR; Hoffmann A; Bergmann R; Arndt C; Koristka S; Mitwasi N; Kegler A; Bartsch T; Berndt N; Altmann H; Fasslrinner F; Bornhäuser M; Bachmann MP; Feldmann A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638268
[TBL] [Abstract][Full Text] [Related]
5. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.
Feldmann A; Hoffmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Rodrigues Loureiro L; Kittel-Boselli E; Mitwasi N; Kegler A; Lamprecht C; González Soto KE; Bachmann M
Oncoimmunology; 2020 Jul; 9(1):1785608. PubMed ID: 32923149
[TBL] [Abstract][Full Text] [Related]
6. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
7. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
8. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
9. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
[TBL] [Abstract][Full Text] [Related]
10. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors.
Golinelli G; Grisendi G; Prapa M; Bestagno M; Spano C; Rossignoli F; Bambi F; Sardi I; Cellini M; Horwitz EM; Feletti A; Pavesi G; Dominici M
Cancer Gene Ther; 2020 Aug; 27(7-8):558-570. PubMed ID: 30464207
[TBL] [Abstract][Full Text] [Related]
11. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
12. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
13. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
16. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
17. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
18. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
[TBL] [Abstract][Full Text] [Related]
20. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
Front Immunol; 2022; 13():864868. PubMed ID: 35935988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
